FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
+19.09%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$2.5B
AUM Growth
+$2.5B
(+17%)
Cap. Flow
+$203M
Cap. Flow
% of AUM
8.14%
Top 10 Holdings %
Top 10 Hldgs %
59.89%
Holding
57
New
8
Increased
13
Reduced
5
Closed
4
Top Buys
| 1 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$155M |
| 2 |
Ascendis Pharma
ASND
|
$19.9M |
| 3 |
Alkermes
ALKS
|
$16.1M |
| 4 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$11.7M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
$11.6M |
Top Sells
| 1 |
Edgewise Therapeutics
EWTX
|
$24M |
| 2 |
Vaxcyte
PCVX
|
$18.3M |
| 3 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$16.1M |
| 4 |
Applied Therapeutics
APLT
|
$10.7M |
| 5 |
PepGen
PEPG
|
$6.84M |
Sector Composition
| 1 | Healthcare | 99.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MREO
26
Mereo BioPharma
MREO
$275M
| $21M | 0.84% |
5,097,779
+696,408
| +16% | +$2.86M |
|
|
SLN
27
Silence Therapeutics
SLN
$237M
| $20.9M | 0.84% |
1,148,591
| – | – |
|
|
28
Ascendis Pharma
ASND
$12.1B
| $19.9M | 0.8% |
+133,333
| New | +$19.9M |
|
29
HilleVax
HLVX
$105M
| $18.7M | 0.75% |
10,617,062
| – | – |
|
30
Merus
MRUS
$5.04B
| $18.6M | 0.75% |
373,100
| – | – |
|
31
Tyra Biosciences
TYRA
$657M
| $17.2M | 0.69% |
731,020
-101,200
| -12% | -$2.38M |
|
|
AUTL
32
Autolus Therapeutics
AUTL
$383M
| $16.8M | 0.67% |
4,623,324
| – | – |
|
|
33
Alkermes
ALKS
$4.95B
| $16.1M | 0.65% |
+576,129
| New | +$16.1M |
|
34
Immatics
IMTX
$662M
| $15.5M | 0.62% |
1,354,711
+202,255
| +18% | +$2.31M |
|
|
ORKA
35
Oruka Therapeutics, Inc. Common Stock
ORKA
$578M
| $11.7M | 0.47% |
+477,327
| New | +$11.7M |
|
36
Lexeo Therapeutics
LXEO
$266M
| $11.3M | 0.45% |
+1,250,786
| New | +$11.3M |
|
37
Design Therapeutics
DSGN
$339M
| $10.2M | 0.41% |
1,892,547
+697,368
| +58% | +$3.75M |
|
38
Cogent Biosciences
COGT
$1.83B
| $10.1M | 0.41% |
936,576
| – | – |
|
39
MacroGenics
MGNX
$121M
| $9.91M | 0.4% |
3,010,727
| – | – |
|
40
Day One Biopharmaceuticals
DAWN
$766M
| $9.61M | 0.39% |
+689,655
| New | +$9.61M |
|
41
Allogene Therapeutics
ALLO
$249M
| $8.03M | 0.32% |
2,867,750
| – | – |
|
42
Puma Biotechnology
PBYI
$258M
| $7.81M | 0.31% |
3,062,558
| – | – |
|
43
Adverum Biotechnologies
ADVM
$68.2M
| $7.51M | 0.3% |
1,069,244
| – | – |
|
44
89bio
ETNB
$1.37B
| $7.4M | 0.3% |
1,000,000
| – | – |
|
45
Acadia Pharmaceuticals
ACAD
$4.34B
| $7.23M | 0.29% |
470,338
| – | – |
|
46
Arvinas
ARVN
$580M
| $7.03M | 0.28% |
285,331
| – | – |
|
|
47
PepGen
PEPG
$39M
| $6.01M | 0.24% |
702,694
-800,094
| -53% | -$6.84M |
|
|
ELEV
48
DELISTED
Elevation Oncology
ELEV
| $3.6M | 0.14% |
5,993,579
+3,035,000
| +103% | +$1.82M |
|
49
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$64M
| $3.5M | 0.14% |
500,333
| – | – |
|
50
Immunocore
IMCR
$1.78B
| $3.39M | 0.14% |
108,762
| – | – |
|